Condition: Chronic Lung Disease · Hematopoietic Cell Transplantation · Graft Versus Host Disease · Sponsor: University of Michigan Rogel Cancer Center
The study will have two separate patient cohorts: Cohort 1 will include patients with newly diagnosed chronic graft versus host disease (GVHD), whereas cohort 2 will include patients with newly diagnosed chronic lung disease (CLD). For cohort 1, the primary objective will be to characterize PRM metrics at the onset of chronic GVHD and determine if a PRM signature is present that will predict 1-year CLD free survival. For cohort 2, the primary objective will focus on characterizing PRM at the onset of CLD and determine if PRM can predict the trajectory in lung function decline in affected patients.
This description comes directly from the study's public registry record.
Cancer Answerline · 1-800-865-1125 · CancerAnswerLine@med.umich.edu
Always discuss trial participation with your own doctor first.
| Stanford Hospital | Stanford, California, United States | Recruiting |
| Emory University | Atlanta, Georgia, United States | Not Yet Recruiting |
| Dana Farber | Boston, Massachusetts, United States | Not Yet Recruiting |
| The University of Michigan Cancer Center | Ann Arbor, Michigan, United States | Recruiting |
| MD Anderson | Houston, Texas, United States | Not Yet Recruiting |
| Fred Hutchinson Cancer Research Center | Seattle, Washington, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05866302